Gilead Sciences (GILD) Share-based Compensation (2009 - 2026)

Gilead Sciences (GILD) has reported Share-based Compensation for 18 consecutive years, with $218.0 million the latest figure, recorded in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $218.0 million, up 4.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $903.0 million (up 5.37% YoY), and the FY2025 annual result was $894.0 million, up 7.07% from the prior year.
• Share-based Compensation was $218.0 million for Q1 2026 at Gilead Sciences, down from $230.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $230.0 million in Q3 2025 and troughed at $130.0 million in Q1 2022.
• Average Share-based Compensation over 5 years is $197.1 million, with a median of $202.0 million recorded in 2023.
• Year-over-year, Share-based Compensation declined 6.47% in 2022 and gained 26.92% in 2023.
• Over 5 years, Share-based Compensation stood at $174.0 million in 2022, then gained by 15.52% to $201.0 million in 2023, then advanced by 10.45% to $222.0 million in 2024, then advanced by 3.6% to $230.0 million in 2025, then retreated by 5.22% to $218.0 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $218.0 million in Q1 2026, $230.0 million in Q4 2025, and $230.0 million in Q3 2025.